|
GS185131: GO:0044699 single-organism process
|
|
GS198398: GO:0050670 regulation of lymphocyte proliferation
|
|
GS135428: bone mechanical trait 7 (Bmch7, Published QTL Chr 17)
|
|
GS170447: MP:0010210 abnormal circulating cytokine level
|
|
GS166302: MP:0002962 increased urine protein level
|
|
GS136704: systemic lupus erythmatosus suppressor 1 (Sles1, Published QTL Chr 17)
|
|
GS169127: MP:0002445 abnormal mononuclear cell differentiation
|
|
GS204481: GO:0070665 positive regulation of leukocyte proliferation
|
|
GS136392: organ weight 10 (Org10, Published QTL Chr 17)
|
|
GS168559: MP:0002421 abnormal cell-mediated immunity
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS169733: MP:0002461 increased immunoglobulin level
|
|
GS84305: differences in cocaine responsiveness (Published QTL, Chr 17)
|
|
GS167046: MP:0003881 abnormal nephron morphology
|
|
GS204611: GO:0019221 cytokine-mediated signaling pathway
|
|
GS136305: modifier of Yaa 2 (Myaa2, Published QTL Chr 17)
|
|
GS170764: MP:0008578 decreased circulating interferon-gamma level
|
|
GS192180: GO:0004896 cytokine receptor activity
|
|
GS168334: MP:0002619 abnormal lymphocyte morphology
|
|
GS136509: particle-induced immune disfunction (Pidys, Published QTL Chr 17)
|
|
GS165992: MP:0008469 abnormal protein level
|
|
GS191035: GO:0005125 cytokine activity
|
|
GS166549: MP:0008613 abnormal circulating interleukin-17 level
|
|
GS203972: GO:0005615 extracellular space
|
|
GS166858: MP:0000685 abnormal immune system morphology
|
|
GS163965: MP:0011182 decreased hematopoietic cell number
|
|
GS170734: MP:0008681 increased interleukin-17 secretion
|
|
GS165630: MP:0005566 decreased blood urea nitrogen level
|
|
GS165136: MP:0003009 abnormal cytokine secretion
|
|
GS170136: MP:0008083 decreased single-positive T cell number
|
|
GS164333: MP:0000516 abnormal renal/urinary system morphology
|
|
GS168343: MP:0008751 abnormal interleukin level
|
|
GS167998: MP:0002409 decreased susceptibility to infection
|
|
GS202162: GO:0005126 cytokine receptor binding
|
|
GS135227: anticardiolipin antibody 1 (Acla1, Published QTL Chr 17)
|
|
GS205500: GO:0071944 cell periphery
|
|
GS166908: MP:0005325 abnormal renal glomerulus morphology
|
|
GS135736: delta power in slow-wave sleep 3 (Dps3, Published QTL Chr 17)
|
|
GS135650: cocaine induced activation 13 (Cocia13, Published QTL Chr 17)
|
|
GS204106: GO:0060089 molecular transducer activity
|
|
GS194715: GO:0046631 alpha-beta T cell activation
|
|
GS194455: GO:0051239 regulation of multicellular organismal process
|
|
GS178426: GO:0005102 receptor binding
|
|
GS136120: body length 9 (Lgth9, Published QTL Chr 17)
|
|
GS201367: GO:0019538 protein metabolic process
|
|
GS136483: plasmacytoma susceptibility 5 (Pcyts5, Published QTL Chr 17)
|
|
GS196808: GO:0032501 multicellular organismal process
|
|
GS123801: Fatty Acids, Omega-3 interacting genes (MeSH:D015525) in CTD
|
|
GS178913: GO:0042221 response to chemical stimulus
|
|
GS202468: GO:0070887 cellular response to chemical stimulus
|
|
GS210178: GO:0031328 positive regulation of cellular biosynthetic process
|
|
GS84307: METH responses for chewing (Published QTL, Chr 17)
|
|
GS167627: MP:0005460 abnormal leukopoiesis
|
|
GS197669: GO:0051246 regulation of protein metabolic process
|
|
GS136437: platelet-binding antibody-associated thrombocytopenia 1 (Pbat1, Published QTL Chr 17)
|
|
GS166678: MP:0010063 abnormal circulating creatine level
|
|
GS165877: MP:0002136 abnormal kidney physiology
|
|
GS208187: GO:0010033 response to organic substance
|
|
GS206329: GO:0060255 regulation of macromolecule metabolic process
|
|
GS164951: MP:0003658 abnormal capillary morphology
|
|
GS135436: bone mineral density 26 (Bmd26, Published QTL Chr 17)
|
|
GS167552: MP:0008499 increased IgG1 level
|
|
GS197666: GO:0051249 regulation of lymphocyte activation
|
|
GS163397: MP:0005265 abnormal blood urea nitrogen level
|
|
GS135782: early growth QTL 5 (Egq5, Published QTL Chr 17)
|
|
GS189751: GO:0050794 regulation of cellular process
|
|
GS169774: MP:0001846 increased inflammatory response
|
|
GS182325: GO:0051716 cellular response to stimulus
|
|
GS195668: GO:0042221 response to chemical stimulus
|
|
GS165171: MP:0008835 abnormal intercellular signaling peptide or protein level
|
|
GS202313: GO:0046651 lymphocyte proliferation
|
|
GS209951: GO:0042127 regulation of cell proliferation
|
|
GS163626: MP:0011445 abnormal renal protein reabsorption
|
|
GS207178: GO:0050867 positive regulation of cell activation
|
|
GS126584: Tetrachlorodibenzodioxin interacting genes (MeSH:D013749) in CTD
|
|
GS163318: MP:0000521 abnormal kidney cortex morphology
|
|
GS167583: MP:0000530 abnormal kidney blood vessel morphology
|
|
GS204478: GO:0070661 leukocyte proliferation
|
|
GS185492: GO:0050789 regulation of biological process
|
|
GS136021: hematopoietic stem cell frequency regulator (Hscfr, Published QTL Chr 17)
|
|
GS181473: GO:0005488 binding
|
|
GS167714: MP:0002414 abnormal myeloblast morphology/development
|
|
GS168996: MP:0009643 abnormal urine homeostasis
|
|
GS196930: GO:0065007 biological regulation
|
|
GS168155: MP:0005502 abnormal renal/urinary system physiology
|
|
GS197694: GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
|
|
GS207616: GO:0016020 membrane
|
|
GS135617: circulating hormone level QTL 9 (Chlq9, Published QTL Chr 17)
|
|
GS136429: pulmonary adenoma susceptibility 2 (Pas2, Published QTL Chr 17)
|
|
GS167542: MP:0001790 abnormal immune system physiology
|
|
GS135370: B.burgdorferi-associated arthritis 8 (Bbaa8, Published QTL Chr 17)
|
|
GS167326: MP:0002145 abnormal T cell differentiation
|
|
GS204746: GO:0080090 regulation of primary metabolic process
|
|
GS136866: T cell receptor induced activation 3 (Tria3, Published QTL Chr 17)
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS192680: GO:0038023 signaling receptor activity
|
|
GS163491: MP:0003304 large intestinal inflammation
|
|
GS168274: MP:0002433 abnormal T-helper 1 cell morphology
|
|
GS181817: GO:0071345 cellular response to cytokine stimulus
|
|
GS184451: GO:0044421 extracellular region part
|
|
GS185340: GO:0005126 cytokine receptor binding
|
|
GS209114: GO:0004896 cytokine receptor activity
|
|
GS193270: GO:0005576 extracellular region
|
|
GS165418: MP:0002490 abnormal immunoglobulin level
|
|
GS199584: GO:0045523 interleukin-27 receptor binding
|
|
GS209199: GO:0007165 signal transduction
|
|
GS168300: MP:0008602 increased circulating interleukin-4 level
|
|
GS135962: HDL QTL 29 (Hdlq29, Published QTL Chr 17)
|
|
GS169037: MP:0010183 abnormal CD4-positive helper T cell morphology
|
|
GS169767: MP:0002396 abnormal hematopoietic system morphology/development
|
|
GS210560: GO:0071310 cellular response to organic substance
|
|
GS207673: GO:0002694 regulation of leukocyte activation
|
|
GS209863: GO:0050896 response to stimulus
|
|
GS169777: MP:0002398 abnormal bone marrow cell morphology/development
|
|
GS187881: GO:0004888 transmembrane signaling receptor activity
|
|
GS194711: GO:0046635 positive regulation of alpha-beta T cell activation
|
|
GS166250: MP:0008247 abnormal mononuclear cell morphology
|
|
GS208012: GO:0044464 cell part
|
|
GS187113: GO:0005615 extracellular space
|
|
GS210212: GO:0005575 cellular_component
|
|
GS84303: differences in cocaine responsiveness (Published QTL, Chr 17)
|
|
GS193929: GO:0042098 T cell proliferation
|
|
GS136385: obesity and body weight QTL 4 (Obwq4, Published QTL Chr 17)
|
|
GS206623: GO:0050794 regulation of cellular process
|
|
GS124805: decitabine interacting genes (MeSH:C014347) in CTD
|
|
GS197924: GO:0046649 lymphocyte activation
|
|
GS208060: GO:0010557 positive regulation of macromolecule biosynthetic process
|
|
GS202901: GO:0050870 positive regulation of T cell activation
|
|
GS170630: MP:0005027 increased susceptibility to parasitic infection
|
|
GS197930: GO:0046640 regulation of alpha-beta T cell proliferation
|
|
GS168422: MP:0000716 abnormal immune system cell morphology
|
|
GS184701: GO:0034097 response to cytokine stimulus
|
|
GS36684: Striatum Gene expression correlates of Morphine vertical activity counts minutes 15-30 in Males BXD
|
|
GS194713: GO:0046633 alpha-beta T cell proliferation
|
|
GS136758: soft tissue heal 11 (Stheal11, Published QTL Chr 17)
|
|
GS169708: MP:0005416 abnormal circulating protein level
|
|
GS123718: Ethinyl Estradiol interacting genes (MeSH:D004997) in CTD
|
|
GS193839: GO:0045072 regulation of interferon-gamma biosynthetic process
|
|
GS136962: weight adult 4 (Wta4, Published QTL Chr 17)
|
|
GS135265: age related hearing loss 3 (Ahl3, Published QTL Chr 17)
|
|
GS163349: MP:0008555 abnormal interferon secretion
|
|
GS164263: MP:0002083 premature death
|
|
GS165616: MP:0002127 abnormal cardiovascular system morphology
|
|
GS169331: MP:0001663 abnormal digestive system physiology
|
|
GS200016: GO:0001817 regulation of cytokine production
|
|
GS135455: body weight 2 (Bodwt2, Published QTL Chr 17)
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS210180: GO:0031326 regulation of cellular biosynthetic process
|
|
GS206291: GO:0032609 interferon-gamma production
|
|
GS205622: GO:0009889 regulation of biosynthetic process
|
|
GS208657: GO:0008284 positive regulation of cell proliferation
|
|
GS166572: MP:0011320 abnormal glomerular capillary morphology
|
|
GS163667: MP:0008568 abnormal interleukin secretion
|
|
GS169773: MP:0001845 abnormal inflammatory response
|
|
GS168845: MP:0002459 abnormal B cell physiology
|
|
GS194226: GO:0045078 positive regulation of interferon-gamma biosynthetic process
|
|
GS136043: insulin dependent diabetes susceptibility 16 (Idd16, Published QTL Chr 17)
|
|
GS206450: GO:0042088 T-helper 1 type immune response
|
|
GS208061: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS196943: GO:0008152 metabolic process
|
|
GS187146: GO:0044700 single organism signaling
|
|
GS206451: GO:0042089 cytokine biosynthetic process
|
|
GS196941: GO:0008150 biological_process
|
|
GS84306: METH responses for home cage activity (Published QTL, Chr 17)
|
|
GS199634: GO:0005623 cell
|
|
GS207176: GO:0050865 regulation of cell activation
|
|
GS164136: MP:0000001 mammalian phenotype
|
|
GS122847: nickel sulfate interacting genes (MeSH:C029938) in CTD
|
|
GS197009: GO:0005886 plasma membrane
|
|
GS201186: GO:0042108 positive regulation of cytokine biosynthetic process
|
|
GS136177: locomotor activity 2 (Loco2, Published QTL Chr 17)
|
|
GS204007: GO:0044700 single organism signaling
|
|
GS210097: GO:0032946 positive regulation of mononuclear cell proliferation
|
|
GS210182: GO:0031323 regulation of cellular metabolic process
|
|
GS163026: MP:0000221 decreased leukocyte cell number
|
|
GS201431: GO:0005515 protein binding
|
|
GS201192: GO:0042102 positive regulation of T cell proliferation
|
|
GS162826: MP:0008539 decreased susceptibility to induced colitis
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS187247: GO:0060089 molecular transducer activity
|
|
GS203371: GO:0002684 positive regulation of immune system process
|
|
GS136861: "T cell receptor beta variable 4, control 1" (Trbv4c1, Published QTL Chr 17)
|
|
GS168551: MP:0002429 abnormal blood cell morphology/development
|
|
GS210181: GO:0031325 positive regulation of cellular metabolic process
|
|
GS168560: MP:0002420 abnormal adaptive immunity
|
|
GS136800: total body bone mineral density 7 (Tbbmd7, Published QTL Chr 17)
|
|
GS136903: ventral midbrain iron content 9 (Vmbic9, Published QTL Chr 17)
|
|
GS201255: GO:0044421 extracellular region part
|
|
GS207675: GO:0002696 positive regulation of leukocyte activation
|
|
GS164243: MP:0008588 abnormal circulating interleukin level
|
|
GS169827: MP:0005387 immune system phenotype
|
|
GS170198: MP:0001614 abnormal blood vessel morphology
|
|
GS166967: MP:0010060 abnormal creatine level
|
|
GS170138: MP:0008081 abnormal single-positive T cell number
|
|
GS204568: GO:0009893 positive regulation of metabolic process
|
|
GS163297: MP:0000217 abnormal leukocyte cell number
|
|
GS170423: MP:0008698 abnormal interleukin-4 secretion
|
|
GS204021: GO:0044707 single-multicellular organism process
|
|
GS170609: MP:0008680 abnormal interleukin-17 secretion
|
|
GS184629: GO:0005515 protein binding
|
|
GS198608: GO:0071345 cellular response to cytokine stimulus
|
|
GS166662: MP:0010062 decreased creatine level
|
|
GS163358: MP:0008559 abnormal interferon-gamma secretion
|
|
GS135924: hepatocarcinogenesis in females 1 (Hcif1, Published QTL Chr 17)
|
|
GS127240: Acetaminophen interacting genes (MeSH:D000082) in CTD
|
|
GS84302: differences in cocaine responsiveness (Published QTL, Chr 17)
|
|
GS179211: GO:0007154 cell communication
|
|
GS185920: GO:0004872 receptor activity
|
|
GS192265: GO:0007165 signal transduction
|
|
GS180152: GO:0065007 biological regulation
|
|
GS168269: MP:0002434 abnormal T-helper 2 cell morphology
|
|
GS202760: GO:0004871 signal transducer activity
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS167711: MP:0002411 decreased susceptibility to bacterial infection
|
|
GS135324: antibody response to human factor IX (Arfix, Published QTL Chr 17)
|
|
GS135763: experimental allergic encephalomyelitis susceptibility 5 (Eae5, Published QTL Chr 17)
|
|
GS202759: GO:0004872 receptor activity
|
|
GS163286: MP:0008045 decreased NK cell number
|
|
GS168273: MP:0002432 abnormal CD4-positive T cell morphology
|
|
GS208664: GO:0008283 cell proliferation
|
|
GS210214: GO:0005576 extracellular region
|
|
GS169173: MP:0006387 abnormal T cell number
|
|
GS136083: keratoconus 1 (Krcn1, Published QTL Chr 17)
|
|
GS200432: GO:0002682 regulation of immune system process
|
|
GS167719: MP:0002816 colitis
|
|
GS164022: MP:0008246 abnormal leukocyte morphology
|
|
GS194586: GO:0002376 immune system process
|
|
GS209622: GO:0038023 signaling receptor activity
|
|
GS209009: GO:1901576 organic substance biosynthetic process
|
|
GS165537: MP:0005376 homeostasis/metabolism phenotype
|
|
GS136773: SGC/Knj cross B6 QTL 3 (Sxbq3, Published QTL Chr 17)
|
|
GS204036: GO:0045321 leukocyte activation
|
|
GS136092: long bones 10 (Lbn10, Published QTL Chr 17)
|
|
GS201265: GO:0009891 positive regulation of biosynthetic process
|
|
GS166598: MP:0005332 abnormal amino acid level
|
|
GS170130: MP:0008089 abnormal T-helper 2 cell number
|
|
GS124403: Fatty Acids, Omega-6 interacting genes (MeSH:D043371) in CTD
|
|
GS194605: GO:0001775 cell activation
|
|
GS202316: GO:0050789 regulation of biological process
|
|
GS194087: GO:0003674 molecular_function
|
|
GS191268: GO:0010033 response to organic substance
|
|
GS166569: MP:0008614 increased circulating interleukin-17 level
|
|
GS167098: MP:0001819 abnormal immune cell physiology
|
|
GS177356: GO:0003674 molecular_function
|
|
GS207940: GO:0005125 cytokine activity
|
|
GS167321: MP:0003945 abnormal lymphocyte physiology
|
|
GS136686: skull morphology 25 (Skull25, Published QTL Chr 17)
|
|
GS136479: periosteal circumference 4 (Pcir4, Published QTL Chr 17)
|
|
GS196837: GO:0042110 T cell activation
|
|
GS164700: MP:0010065 decreased circulating creatine level
|
|
GS169855: MP:0008091 decreased T-helper 2 cell number
|
|
GS201504: GO:0034097 response to cytokine stimulus
|
|
GS198399: GO:0050671 positive regulation of lymphocyte proliferation
|
|
GS163361: MP:0010107 abnormal renal reabsorbtion
|
|
GS210095: GO:0032943 mononuclear cell proliferation
|
|
GS197931: GO:0046641 positive regulation of alpha-beta T cell proliferation
|
|
GS204740: GO:0004888 transmembrane signaling receptor activity
|
|
GS170362: MP:0000717 abnormal lymphocyte cell number
|
|
GS135592: P. chabaudi malaria resistance QTL 7 (Char7, Published QTL Chr 17)
|
|
GS128599: Ethanol Induced Ataxia Chr#17
|
|
GS136942: weight 10 weeks QTL 12 (W10q12, Published QTL Chr 17)
|
|
GS202077: GO:0051251 positive regulation of lymphocyte activation
|
|
GS84304: Hprt-ps1 (Published QTL, Chr 17)
|
|
GS187750: GO:0019221 cytokine-mediated signaling pathway
|
|
GS167545: MP:0001793 altered susceptibility to infection
|
|
GS168848: MP:0002452 abnormal antigen presenting cell physiology
|
|
GS168344: MP:0008750 abnormal interferon level
|
|
GS165876: MP:0002135 abnormal kidney morphology
|
|
GS190714: GO:0016020 membrane
|
|
GS169424: MP:0005558 decreased creatinine clearance
|
|
GS199776: GO:0006959 humoral immune response
|
|
GS209480: GO:0006955 immune response
|
|
GS195214: GO:0009987 cellular process
|
|
GS163934: MP:0001764 abnormal homeostasis
|
|
GS199124: GO:0051716 cellular response to stimulus
|
|
GS136562: radiation pulmonary fibrosis 1 (Radpf1, Published QTL Chr 17)
|
|
GS169457: MP:0008700 decreased interleukin-4 secretion
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS135781: early growth adjusted QTL 2 (Egaq2, Published QTL Chr 17)
|
|
GS203318: GO:0042035 regulation of cytokine biosynthetic process
|
|
GS198263: GO:0005488 binding
|
|
GS206355: GO:0023052 signaling
|
|
GS192918: GO:0050896 response to stimulus
|
|
GS135896: gastritis type A susceptibility locus 4 (Gasa4, Published QTL Chr 17)
|
|
GS194712: GO:0046634 regulation of alpha-beta T cell activation
|
|
GS165524: MP:0010769 abnormal survival
|
|
GS182786: GO:0045523 interleukin-27 receptor binding
|
|
GS170417: MP:0008075 decreased CD4-positive T cell number
|
|
GS163280: MP:0008043 abnormal NK cell number
|
|
GS195977: GO:0007154 cell communication
|
|
GS206820: GO:0032649 regulation of interferon-gamma production
|
|
GS165312: MP:0011310 abnormal kidney capillary morphology
|
|
GS185637: GO:0070887 cellular response to chemical stimulus
|
|
GS194267: GO:0043170 macromolecule metabolic process
|
|
GS210357: GO:0044249 cellular biosynthetic process
|
|
GS135644: cerebral malaria susceptibility in CBA/N (Cmcs, Published QTL Chr 17)
|
|
GS193614: GO:0071310 cellular response to organic substance
|
|
GS168270: MP:0002435 abnormal effector T cell morphology
|
|
GS203057: GO:0048518 positive regulation of biological process
|
|
GS165798: MP:0005367 renal/urinary system phenotype
|
|
GS167589: MP:0005016 decreased lymphocyte cell number
|
|
GS180164: GO:0008150 biological_process
|
|
GS136546: periosteal circumference 5 (Pstc5, Published QTL Chr 17)
|
|
GS874: Differential expression in Meander-tail (mea) vs. BLKS controls.
|
|
GS167186: MP:0008601 abnormal circulating interleukin-4 level
|
|
GS168995: MP:0009642 abnormal blood homeostasis
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS169027: MP:0005556 abnormal kidney clearance
|
|
GS169829: MP:0005385 cardiovascular system phenotype
|
|
GS169917: MP:0010155 abnormal intestine physiology
|
|
GS185921: GO:0004871 signal transducer activity
|
|
GS166923: MP:0002827 abnormal renal corpuscle morphology
|
|
GS170081: MP:0001858 intestinal inflammation
|
|
GS207858: GO:0009059 macromolecule biosynthetic process
|
|
GS163560: MP:0008037 abnormal T cell morphology
|
|
GS195176: GO:0005102 receptor binding
|
|
GS136614: colon tumor susceptibility 4 (Scc4, Published QTL Chr 17)
|
|
GS165417: MP:0002493 increased IgG level
|
|
GS197670: GO:0051247 positive regulation of protein metabolic process
|
|
GS209953: GO:0042129 regulation of T cell proliferation
|
|
GS136943: weight 6 weeks QTL 11 (W6q11, Published QTL Chr 17)
|
|
GS163681: MP:0008566 increased interferon-gamma secretion
|
|
GS167566: MP:0005018 decreased T cell number
|
|
GS198685: GO:0048522 positive regulation of cellular process
|
|
GS201949: GO:0044699 single-organism process
|
|
GS200015: GO:0001816 cytokine production
|
|
GS135590: P. chabaudi malaria resistance QTL 3 (Char3, Published QTL Chr 17)
|
|
GS163353: MP:0008551 abnormal circulating interferon-gamma level
|
|
GS178461: GO:0009987 cellular process
|
|
GS136833: trypanosome infection response 1 (Tir1, Published QTL Chr 17)
|
|
GS135229: Angiostrongylus costaricensis nematode susceptibility 3 (Acsns3, Published QTL Chr 17)
|
|
GS207182: GO:0050863 regulation of T cell activation
|
|
GS162984: MP:0001800 abnormal humoral immune response
|
|
GS201728: GO:0002250 adaptive immune response
|
|
GS193268: GO:0005575 cellular_component
|
|
GS209215: GO:0007166 cell surface receptor signaling pathway
|
|
GS169589: MP:0008713 abnormal cytokine level
|
|
GS164881: MP:0005068 abnormal NK cell morphology
|
|
GS207857: GO:0009058 biosynthetic process
|
|
GS192279: GO:0007166 cell surface receptor signaling pathway
|
|
GS163956: MP:0011180 abnormal hematopoietic cell number
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS167997: MP:0002406 increased susceptibility to infection
|
|
GS35238: Neocortex Gene expression correlates of Background startle response in Males BXD
|
|
GS127205: Tamoxifen interacting genes (MeSH:D013629) in CTD
|
|
GS201189: GO:0042107 cytokine metabolic process
|
|
GS167991: MP:0002401 abnormal lymphopoiesis
|
|
GS204612: GO:0019222 regulation of metabolic process
|
|
GS163106: MP:0008548 abnormal circulating interferon level
|
|
GS136157: leishmaniasis resistance 1 (Lmr1, Published QTL Chr 17)
|
|
GS165421: MP:0002497 increased IgE level
|
|
GS135462: bleomycin pulmonary fibrosis 1 (Bplpf1, Published QTL Chr 17)
|
|
GS164133: MP:0005076 abnormal cell differentiation
|
|
GS170748: MP:0005025 abnormal response to infection
|
|
GS210099: GO:0032944 regulation of mononuclear cell proliferation
|
|
GS169133: MP:0002442 abnormal leukocyte physiology
|
|
GS83968: cocaine induced activation 13 (Cocia13, Published QTL, Chr 17)
|
|
GS163797: MP:0006315 abnormal urine protein level
|
|
GS135486: bone response to mechanical loading 6 (Brml6, Published QTL Chr 17)
|
|
GS136887: UVB induced immunosuppression 2 (Uvbi2, Published QTL Chr 17)
|
|
GS135256: adenovirus induced hyperthyroidism 2 (Advh2, Published QTL Chr 17)
|
|
GS204479: GO:0070663 regulation of leukocyte proliferation
|
|
GS135687: CD86 expression in activated macrophages (Cxam, Published QTL Chr 17)
|
|
GS167222: MP:0005311 abnormal circulating amino acid level
|
|
GS193927: GO:0042095 interferon-gamma biosynthetic process
|
|
GS189484: GO:0023052 signaling
|
|
GS198572: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS135861: femur breaking strength 4 (Fembrs4, Published QTL Chr 17)
|
|
GS851: Sey_Pax6_Int_Lin_Inc_No_Change
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS135296: acute lung injury QTL 3 (Aliq3, Published QTL Chr 17)
|
|
GS169832: MP:0005381 digestive/alimentary phenotype
|
|
GS170411: MP:0008073 abnormal CD4-positive T cell number
|
|
GS165474: MP:0002723 abnormal immune serum protein physiology
|